πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

ALMIRALL S.P.A Patents

Full USPTO pharma patent portfolio for ALMIRALL S.P.A β€” grant dates, expiration, and drug cross-links.

Patents
308
Expiring ≀24m
14

Quick answer

ALMIRALL S.P.A has 308 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 14 expire within 24 months β€” use filters for patent-cliff planning.

Page 3 of 7

  1. US 10214509

    Amino-substituted heterocyclic derivatives as sodium channel inhibitors

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10208089

    Modulation of complement activity

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10173985

    Aminoindazole derivatives as sodium channel inhibitors

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10144930

    Inhibitors of MYH7B and uses thereof

    Expires Mon Nov 29 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10125134

    KRas G12C inhibitors

    Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10106579

    Modulation of complement activity

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10092736

    Device and method for dispensing a drug

    Expires Mon Oct 04 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10085974

    Dosage and formulation

    Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10059668

    LSD1 inhibitors

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10039775

    Preparation method for antitumor drug AP26113

    Expires Mon Aug 02 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10034867

    Quinuclidine derivatives and medicinal compositions containing the same

    Expires Mon Jul 26 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10011833

    Bridged bicyclic nucleosides

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10004717

    Glycopyrrolate salts

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10005771

    Bicyclic derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

    Expires Mon Jun 21 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9999650

    Peptide and peptidomimetic inhibitors

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10000456

    Polycyclic compounds as lysophosphatidic acid receptor antagonists

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9994847

    miR-29 mimics and uses thereof

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9994852

    Oligonucleotide compositions and uses thereof

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9975867

    Synthetic process for preparing 2-furoic acid derivatives

    Expires Mon May 17 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9937222

    Modulators of complement activity

    Expires Mon Apr 05 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9907807

    Topical pharmaceutical compositions

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9885042

    miR-92 inhibitors and uses thereof

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9850244

    Method for preparing Palbociclib

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9849109

    Autotaxin inhibitors and uses thereof

    Expires Mon Dec 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9809541

    LSD1 inhibitors

    Expires Mon Nov 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9803202

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9801874

    Method for the preparation of liposome encapsulated vincristine for therapeutic use

    Expires Mon Oct 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9782382

    TOFA analogs useful in treating dermatological disorders or conditions

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9771585

    miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)

    Expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9757383

    Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

    Expires Mon Sep 07 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9752143

    Locked nucleic acid inhibitor of miR-145 and uses thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9752144

    Inhibitors of MYH7B and uses thereof

    Expires Mon Aug 31 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9737520

    Aclidinium for use in improving the quality of sleep in respiratory patients

    Expires Mon Aug 17 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9687478

    Quinuclidine derivatives and medicinal compositions containing the same

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9670268

    Pharmaceutical composition and method of preparing same

    Expires Mon Jun 01 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9643961

    Cyclohexylamine derivatives having Ξ²2 adrenergic antagonist and M3 muscarinic antagonist activities

    Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9644004

    Peptide and peptidomimetic inhibitors

    Expires Mon May 04 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9624182

    Compounds as lysophosphatidic acid receptor antagonists

    Expires Mon Apr 13 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9610278

    Glycopyrrolate salts

    Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9579316

    Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist activities

    Expires Mon Feb 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9562039

    Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both Ξ²2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities

    Expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9556133

    Polycyclic LPA1 antagonist and uses thereof

    Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9549934

    Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

    Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9518050

    Cyclohexyl and quinuclidinyl carbamate derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activity

    Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9440056

    Device and method for dispensing a drug

    Expires Mon Sep 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9434718

    TOFA analogs useful in treating dermatological disorders or conditions

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9434720

    Pyrazolylbenzothiazole derivatives and their use as therapeutic agents

    Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9416360

    Base modified oligonucleotides

    Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does ALMIRALL S.P.A have?

308 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do ALMIRALL S.P.A patents expire?

14 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.